ORPHA:396
Chronic hiccup
Publications
49
31.9th percentile
Trials
0
Interventional, condition-specific
Researchers
135
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Chronic hiccup is a rare movement disorder characterized by involuntary spasmodic contractions of the inspiratory muscles synchronized with larynx closure lasting for more than 48 hours.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018334
- UMLS:C0744898
Additional Mondo synonyms (1)
Hiccups, Chronic
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
49 matched papers (14 in last 10 years) Source
- Phenotype characterisedPresent
9 HPO annotations (e.g. Recurrent singultus; Depression; Abnormality of the diaphragm) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
9
Associated phenotypes · MONDO:0018334
- Recurrent singultus
- Depression
- Abnormality of the diaphragm
- Weight loss
- Dehydration
Showing 5 of 9 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
49
49 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
49 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
14 in the last 10 years · high confidence · 31.9th percentile (publications denominator)
Phrase hits: 49 · MeSH hits: 0
Who's working on it?
135
Distinct author names in 49 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Bizec JL4 papers · 2010Papers in Europe PMC
- 02Cabane J4 papers · 2010
Service de Médecine Interne (Pr J. C. IMBERT), Hôpital Saint-Antoine, Paris.
Papers in Europe PMC - 03Derenne JP4 papers · 2010Papers in Europe PMC
- 04Petroianu G3 papers · 2000
Department of Pharmacology and Toxicology, University of Heidelberg at Mannheim, Germany.
Papers in Europe PMC - 05Bergler W2 papers · 2000Papers in Europe PMC
- 06Hein G2 papers · 2000Papers in Europe PMC
- 07Launois S2 papers · 1993
Service de Pneumologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Papers in Europe PMC - 08Rüfer R2 papers · 2000Papers in Europe PMC
- 09Similowski T2 papers · 1995Papers in Europe PMC
- 10Whitelaw WA2 papers · 1995Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 64 · after dedupe 62 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 62 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (62)
- isrctn·ISRCTN14373275·Recruiting·Using the antidote flumazenil to treat coma following unintentional drug overdose
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45282100·No longer recruiting·A study to test the safety and effects of a new CB1 antagonist ANEB-001 in healthy occasional cannabis users
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13439529·No longer recruiting·A study to assess nicotine uptake into the blood from and liking of two tobacco heating products compared to cigarettes and a nicotine replacement therapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN81075760·No longer recruiting·A study to examine health effect indicators when a smoker switches to using a tobacco heating product
skipped — LLM skipped (--skip-llm)
- ctis·2026-526368-18-00·Authorised·A Randomized Controlled Study Evaluating Short-Term Dual Antiplatelet Therapy with Low-Dose Ticagrelor (60 mg) Followed by Monotherapy versus Standard-Duration Dual Antiplatelet Therapy with Clopidogrel in Patients with Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: the STELAR trial
skipped — LLM skipped (--skip-llm)
- ctis·2025-523994-41-00·Authorised·A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)
skipped — LLM skipped (--skip-llm)
- ctis·2025-525042-22-00·Authorised·A Study to Evaluate the Safety and Activity of an Inhaled Investigational Drug (RO7616605) in Healthy Volunteers and Participants With COPD
skipped — LLM skipped (--skip-llm)
- ctis·2026-526804-59-00·Authorised·Real-World Effectiveness of the Adjuvanted RSVPreF3 Vaccine in Adults ≥60 Years: A Pragmatic Randomized Trial (BronquiVal)
skipped — LLM skipped (--skip-llm)
- ctis·2025-524842-89-00·Authorised·HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)
skipped — LLM skipped (--skip-llm)
- ctis·2025-523293-17-00·Authorised·SUNCET: Low sodium oxybate Use for Nocturnal Cluster headache: safety, Efficacy and Tolerability of XYWAV - a Phase 2 Randomized, Double-Blind, Placebo-Controlled, bi-center Study
skipped — LLM skipped (--skip-llm)
- ctis·2026-525234-39-00·Authorised·A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
skipped — LLM skipped (--skip-llm)
- ctis·2026-526237-26-00·Authorised, ongoing·A Trial to Evaluate the Safety and Drug Levels of Single and Multiple Oral Doses of AT-587 in Healthy Adults
skipped — LLM skipped (--skip-llm)
- ctis·2025-522165-30-00·Authorised·An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Xembify versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
skipped — LLM skipped (--skip-llm)
- ctis·2025-524374-42-00·Authorised·Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant recipients: A phase 2 trial
RSVaxID
skipped — LLM skipped (--skip-llm)
- ctis·2024-518016-39-00·Authorised, recruiting·A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype
skipped — LLM skipped (--skip-llm)
- ctis·2026-525442-30-00·Authorised·The RELEASE Trial: Reconsidering Long-Term Aspirin in the Elderly in Secondary Prevention of Cardiovascular Disease
skipped — LLM skipped (--skip-llm)
- ctis·2024-520319-42-01·Authorised·A Randomized, Delayed-Treatment Controlled, Phase 2 Pilot Study of Manualized MDMA-Assisted Therapy for Young Adults with Chronic Treatment-Resistant Major Depressive Disorder
skipped — LLM skipped (--skip-llm)
- ctis·2026-526840-10-00·Authorised·Bioequivalence Study of Dapagliflozin 10 mg
skipped — LLM skipped (--skip-llm)
- ctis·2026-526334-67-00·Authorised, recruiting·C6501003 - A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study to Assess Relative Bioavailability of PF-08653945 When Administered Across Different Injection Sites in Adults With Overweight or Obesity
skipped — LLM skipped (--skip-llm)
- ctis·2025-524855-30-00·Authorised·A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
skipped — LLM skipped (--skip-llm)
- ctis·2025-524148-36-00·Authorised·Randomised open-label pilot Study on Thiamine supplementation to REduce braiN injury associated with chronic Alcohol use in outpatients with alcohol use disorder : STRENA
skipped — LLM skipped (--skip-llm)
- ctis·2025-524019-35-00·Authorised, ongoing·Three-part PK and PD study of AXN-027
skipped — LLM skipped (--skip-llm)
- ctis·2025-524722-17-00·Authorised·Short and long-term Hemodynamic and Physiological Effects of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
skipped — LLM skipped (--skip-llm)
- ctis·2025-524795-35-00·Authorised·Phase IV study evaluating the efficacy and safety of the venetoclax + rituximab (VR) regimen in patients with relapsed chronic lymphocytic leukemia in Polish clinical practice
skipped — LLM skipped (--skip-llm)
- ctis·2025-524312-11-00·Authorised·Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) – a randomized, prospective, multicenter, open-label, controlled phase III trial
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Chronic hiccup — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Chronic hiccup" OR "Hiccups, Chronic"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Chronic hiccup" OR "Hiccups, Chronic"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T13:42:28.163Z